Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Is the cost of anticancer therapy justified?

This article was originally published in Scrip

Executive Summary

We all know that cardiovascular disease and cancer are the biggest causes of death in the developed world, but other types of disease impose a much greater overall burden of morbidity. For example, Datamonitor figures show that in the US in 2013 a total of 168.2 million patients were recorded with metabolic diseases such as diabetes, obesity, osteoporosis and lipid disorders, while 144.5 million patients were affected by CNS disorders that varied from migraine, depression, schizophrenia, and epilepsy to Alzheimer’s disease, Parkinson’s disease and multiple sclerosis. In contrast, only 1.2 million cancer patients were recorded in the US in the whole of 2013. Cardiovascular disease came somewhere in between, with 85.1 million patients recorded with conditions such as hypertension, acute coronary syndrome, atrial fibrillation, myocardial infarction and stroke.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC024918

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel